Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06835283 · ClinicalTrials.gov registry record · NA

Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease

A NA study of Alzheimer Disease and Alzheimer's Disease Related Dementia, sponsored by Baylor College of Medicine.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06835283: Recruiting NA study of Alzheimer Disease and Alzheimer's Disease Related Dementia, sponsored by Baylor College of Medicine.

NCT06835283 is a NA study of Alzheimer Disease and Alzheimer's Disease Related Dementia that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 20 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06835283, a NA study of Alzheimer Disease and Alzheimer's Disease Related Dementia, is actively recruiting participants, sponsored by Baylor College of Medicine.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The goal of this pilot study is to test a combination of two non-invasive brain stimulation methods, called iTBS (intermittent theta burst stimulation) and tDCS (transcranial direct current stimulation), in people with Alzheimer's Disease (AD) and related dementias (ADRD). This study will also explore whether the combined treatment shows promise for reducing neuropsychiatric symptoms like mood swings, apathy, and agitation, and will evaluate the impact of the treatment on caregivers. The main questions the study aims to answer are: 1. Is the combined brain stimulation treatment practical and well-tolerated? 2. Do preliminary results suggest that this treatment could help manage neuropsychiatric symptoms and support a larger study? Participants will: * Attend nine in-person visits over three months. * Complete one week of in-clinic brain stimulation sessions (iTBS) followed by four weeks of daily at-home brain stimulation sessions (tDCS). * Take part in brain scans, questionnaires, and brain activity tests before and after the treatment. This pilot study is a first step to assess whether this combined treatment approach is practical and whether it has potential to improve symptoms, laying the groundwork for larger studies in the future.

Primary Outcome

The feasibility of providing sequential iTBS-tDCS treatment to ADRD patients with neuropsychiatric symptoms is a primary focus. Feasibility will be assessed mainly through rates of by recruitment, retention and adherence. Recruitment rate is the number of enrolled patients divided by the total number of patients who initially approached the study or had interest in it. Retention rate is the percentage of patients who complete the entire study out of the initial enrolled participants, and then ad

Interventions

  • DEVICE Brain Stimulation

Study Locations (1)

Texas

  • Michael E. DeBakey VA Medical Center - Houston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-08-11
Est. Completion 2026-09
Phase NA
Baylor College of Medicine

616 total trials

What NCT06835283 shows while recruiting

NCT06835283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Brain Stimulation is the first listed.

NCT06835283 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06835283 about?

NCT06835283 is a clinical study titled "Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease". The goal of this pilot study is to test a combination of two non-invasive brain stimulation methods, called iTBS (intermittent theta burst stimulation) and tDCS (transcranial direct current stimulation), in people with Alzheimer's Disease (AD) and related dementias (ADRD). This study will also explo...

What is the current status of trial NCT06835283?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-08-11. Estimated completion is 2026-09.

What conditions does trial NCT06835283 study?

This clinical trial studies the following conditions: Alzheimer Disease, Alzheimer's Disease Related Dementia, rTMS Stimulation.

What interventions are being tested in trial NCT06835283?

The interventions under investigation include: Brain Stimulation (DEVICE).

Who is sponsoring clinical trial NCT06835283?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06835283 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06835283's enrollment target sits among peer trials

20 264th of 306 higher than 32 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06835283, the US trial registry maintained by the National Library of Medicine. NCT06835283 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.